Akari Therapeutics

Management rationally reprioritized to a single focused oncology modality post‑merger and is outsourcing manufacturing to conserve fixed costs. However, progress depends on continual external capital and has involved repeated small financings, warrants, an ELOC, and a share‑ratio change to maintain listing compliance.

Stock‑based compensation and potential future dilution are meaningful for a company of this size. While the strategy is more coherent post‑merger, the capital structure remains fragile and shareholder‑unfriendly under stress.